“Increasing Adoption of Immunotherapy Treatments”
- One key trend in the Gastroesophageal Junction (GEJ) adenocarcinoma therapeutics market is the increasing adoption of immunotherapy treatments. Immunotherapy, particularly immune checkpoint inhibitors, has gained significant traction in recent years as a promising treatment for GEJ adenocarcinoma. These therapies work by enhancing the body's immune system to target and destroy cancer cells more effectively
- For Instance, in November 2023, Pembrolizumab (Keytruda) was approved for the treatment of advanced or metastatic GEJ adenocarcinoma by the FDA. Pembrolizumab, a PD-1 inhibitor, showed promising results in clinical trials, offering a new line of defense for patients who have not responded to traditional chemotherapy
- This shift towards immunotherapy is driven by its potential to improve patient outcomes, reduce side effects compared to conventional therapies, and extend survival rates. As a result, the adoption of immunotherapies is expected to continue growing, influencing the market's expansion
